NeurAxis Inc.
NRXS | AMEX
$7.14
-$0.47 (-6.18%)
At close: Sep 21, 2026, 4:00 PM ET
$7
-$0.14 (-1.96%)
Pre-market:
Sep 22, 2026, 7:01 AM ET
Company Profile
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Key Executives
| Name | Position |
|---|---|
| Brian Carrico | President, Chief Executive Officer & Director |
| Timothy Robert Henrichs | Chief Financial Officer |
| Adrian Miranda | Senior Vice President of Science & Technology and Chief Medical Officer |
| Behnam Shamsian | Investor Relations |
| Christopher Robin Brown | Founder, Director of Innovation & Director |
| Ryan Kuhlman | Vice President of Sales |
| Thomas Carrico | Chief Regulatory Officer and Compliance & Privacy Officer |
| Trisha Baumgardt | Vice President of Marketing |
NeurAxis Inc.
| Country | United States |
| IPO Date | Aug 8, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Brian Carrico |
Contact Details
11550 North Meridian Street Carmel,
Indiana 46032 United States
Stock Details
| Ticker Symbol | NRXS |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001933567 |
| CUSIP Number | 64134X201 |
| ISIN Number | US64134X2018 |
| SIC Code | 3845 |
Add to Watchlist
Select watchlists to add or remove NRXS